Vol 5, No 4 (2014)
Review paper
Published online: 2015-03-06
Page views
568
Article views/downloads
1647
The cardio-vascular safety of tyrosine kinase inhibitors
Hematologia 2014;5(4):265-271.
Abstract
A literature review is presented that focuses on cardiovascular complications on those patients suffering from chronic myelogenous leukemia that were treated with the 3 most commonly used tyrosine kinase inhibitors; imatinib, nilotinib or dasatinib. An appropriate scheme for their cardiac monitoring is also proposed.
Keywords: tyrosine kinase inhibitorscardio-vascular complications
